Benoit You, MD, PhD, Centre Hospitalier Lyon-Sud, Saint-Genis-Laval, France, discusses the Phase II TROPHIMMUN trial (NCT03135769) of avelumab in young female patients with chemo-resistant gestational trophoblastic tumors. The trial had two cohorts; patients in cohort A were resistant to single-agent chemotherapy, while patients in cohort B were resistant to polychemotherapy. Results from cohort A were reported last year, and were very promising, with 50% of patients being cured with avelumab. Results from cohort B were reported this year and were not as successful, with only 1 out of 7 patients reaching the primary endpoint of successful normalisation of hCG assays. The safety profile in both cohorts was tolerable. This interview took place at the European Society of Gynaecological Oncology (ESGO) 2021 congress in Prague.
